

Active substances set

Search phrase: mirvetuximab soravtansine

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant ovarian cancer

**Mirvetuximab
soravtansine**

Mirvetuximab soravtansine as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FR α) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

 **NO REIMBURSEMENT**

 **ESMO**